SLU-PP-332 is a synthetic small molecule that acts as a pan-ERR (estrogen-related receptor) agonist, activating ERRalpha, ERRbeta, and ERRgamma. It is classified as an exercise mimetic - a compound that can replicate some of the molecular effects of physical exercise without actual physical activity. Despite the name, estrogen-related receptors do NOT bind estrogen and have no estrogenic activity.
Quick Start
Route
Experimental - no established human route. Injectable (DMSO co-solvent required) and oral products both sold; oral lacks bioavailability.
Start low
No validated human dose Oral
Frequency
N/A - no human protocol exists
Timing
Anytime
Starting dose. No validated human dose - preclinical (mouse) data only, not for human use
No human dosing protocol exists. Animal exposures must not be scaled into a human dose.
❋
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Tiered Protocols · lowest first
Conservative start
No validated human dose - preclinical (mouse) data only, not for human use · Experimental - no established human route. Injectable (DMSO co-solvent required) and oral products both sold; oral lacks bioavailability. · N/A - no human protocol exists
conservative starter
No validated human dose - preclinical (mouse) data only, not for human use
N/A - no human protocol exists
Reconstitution CalculatorU-100
050100u
Draw to
— units
◆
◆
◆
01
How it works
Activates all three estrogen-related receptors (ERRalpha EC50=98nM, ERRbeta EC50=230nM, ERRgamma EC50=430nM) with 4.4x selectivity for ERRalpha over ERRgamma. Despite the name, ERRs are orphan nuclear receptors with NO estrogenic activity.
ERRalpha activation upregulates PGC-1alpha, the master regulator of mitochondrial biogenesis, driving increased mitochondrial density, enhanced fatty acid oxidation, and improved oxidative phosphorylation capacity in skeletal muscle.
Induces conversion of glycolytic type IIb muscle fibers to oxidative type IIa fibers, mimicking the fiber-type shift seen with endurance training. Also activates the Ddit4 gene program associated with acute aerobic exercise.
02
What to expect
Early
Days 1–7
Days 1-7: Subtle metabolic effects beginning. Possible mild increase in energy and exercise tolerance.
03
Evidence
HumanNo published trials
AnimalPresent
In-vitroPresent
Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
Previously, we described the development of SLU-PP-332, an agonist for the estrogen-related receptor (ERR)α, β, and γ nuclear receptors that activates an acute aerobic exercise program.
Previously, we described the development of SLU-PP-332, an agonist for the estrogen-related receptor (ERR)α, β, and γ nuclear receptors that activates an acute aerobic exercise program.
Evidence scope. Preclinical mouse work; no established human route, dose, or safety.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Dose/route: No validated human dose - preclinical (mouse) data only, not for human use via Experimental - no established human route. Injectable (DMSO co-solvent required) and oral products both sold; oral lacks bioavailability., N/A - no human protocol exists. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.
Primary safety claim: No significant adverse effects reported in animal studies. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.
04
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
BPC-157No interaction - tissue repair peptide works via distinct pathways
NAD+Complementary - SLU-PP-332 drives mitochondrial biogenesis, NAD+ supports electron transport
Urolithin AComplementary mitochondrial quality - urolithin A clears damaged mitochondria, SLU-PP-332 builds new ones
Keep separate
CYP3A4 inhibitors (ketoconazole, grapefruit)SLU-PP-332 is metabolized by CYP3A4 - inhibitors may increase plasma levels unpredictably
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Hepatic (CYP3A4 metabolism) with renal excretion of metabolites
Storage. Lyophilized powder: -20C, dry, protected from light. Reconstituted: 2-8C (refrigerated), use within 14 days. Oral capsules: room temperature, cool and dry.
06
Regulatory status
Preclinical / research-use-only. No human dose, PK, or safety data exists. Research chemical. Not FDA-approved for any indication. No IND filed. Not scheduled or controlled. Available from research chemical and peptide vendors as lyophilized powder or oral capsules. CAS: 303760-60-3.
Put it to work
Calculate, log & track
Open SLU-PP-332 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.